Intera Atlas
Run match
Sites / Helios Clinical Research
Is this you?

Request access for Helios Clinical Research with your @heliosclinical.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.

Request account

Helios Clinical Research

Unclaimed profile

SMO · US multi-site (Bethesda/Grant Avenue Capital location) · ~20+ sites

WebsiteLinkedInRank for protocol
Intera lens
ICP 8Lift (cardio sample) 0.43Recruit soph 0.57
Quality Scorecard (1–100)
Overall76Recruit76Ops76Sponsor78Ther74

Performance (observed)

Historical trials
271
Completed
104
Terminated/Withdrawn
30
Completion rate
78%
Active now
137
Phase 2
53
Phase 3
195
Realized enrollment
475,686
First study year
2001
Years active
25
Match confidence
high
Enrollment velocity (inf)
19,027

Therapeutic

Areas
Metabolic, urology, vaccines, orthopedics, dermatology, gastroenterology, oncology, general medicine
Specialties
Multi-speciality, phase II-IV focus
Breadth (conditions)
262
States
Multiple (expanding across 4 states initially)

Recruitment (web observed)

Trial Finder
Yes
Patient database
Y (AI-enabled patient identification)
Recruitment pages
Yes
Advertises recruitment
Yes
Capability notes
AI-enabled patient identification, enrollment acceleration, hub-and-spoke operating model, embedded research in health systems

Relationships

Sponsors
Hoffmann-La Roche; Merck Sharp & Dohme LLC; Boehringer Ingelheim; Gilead Sciences; Pfizer; Eli Lilly and Company
CROs
IQVIA Pty Ltd; Premier Research; Worldwide Clinical Trials
Partnerships
Providence Clinical Research partnership
Owner / parent
Grant Avenue Capital (PE-backed, launched 2022)
Expansion
Hub-and-spoke model expansion implied

Capacity & people

Investigators
—
Coordinators
—
CEO
EB McLindon
VP Clinical Ops
Kim Kundert (Senior VP Clinical Operations, BSN)
VP Site Ops
Unknown (Amy Arnold listed as Senior VP)
VP Recruitment
Unknown

Tech & DCT

eSource
Yes
eConsent
Yes
Uses AI
Yes
Builds tech
Vendors (partnership-based approach mentioned)
Tech stack
AI-enabled patient identification and recruitment tools, centralized research infrastructure platform
Recruiting visible
Y

Notes

PE-backed integrated site network launched 2022 (clear growth signal). 20+ sites with AI/recruitment tech focus. Multiple therapeutic areas. Founder EB McLindon came from ICON (Site/Patient/DCT Solutions SVP). Chair Dr. Stephen DeCherney is clinically led. Strong recruitment and enrollment focus. Excellent fit: Growth-backed, multi-site, AI/tech-forward, explicit recruitment focus, nimble PE structure. [Validated: 2 active recruiting cardiometabolic trials on ClinicalTrials.gov.]

Recommendation features (sample indication)

Ind fit 1.00Liftability 0.43Overall76

FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.